Abstract
Recent clinical trials in cancer therapy have demonstrated unprecedented responses through blockade of CTLA-4 and PD-1 immune checkpoint pathways. In a provocative recent paper in Science Translational Medicine, Hatfield and colleagues demonstrate the ability of supplemental oxygen to act as a novel immune checkpoint inhibitor by disrupting the hypoxia-adenosine-A2aR pathway. Recent clinical trials in cancer therapy have demonstrated unprecedented responses through blockade of CTLA-4 and PD-1 immune checkpoint pathways. In a provocative recent paper in Science Translational Medicine, Hatfield and colleagues demonstrate the ability of supplemental oxygen to act as a novel immune checkpoint inhibitor by disrupting the hypoxia-adenosine-A2aR pathway.
Original language | English (US) |
---|---|
Pages (from-to) | 435-436 |
Number of pages | 2 |
Journal | Cancer cell |
Volume | 27 |
Issue number | 4 |
DOIs | |
State | Published - Apr 13 2015 |
ASJC Scopus subject areas
- Oncology
- Cell Biology
- Cancer Research